Skip to content

Author

Yu-Xiang Wu

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Hierarchical Composite Endpoints for Dose Optimization in Early Phase Oncology Trials

A novel benefit–risk assessment framework for DO in early‐phase oncology trials, utilizing hierarchical composite endpoints (HCEs), which extends the HCE method to incorporate pharmacokinetic data through a probabilistic index model, allowing drug exposure to support dose selection.

Yu-Xiang Wu, Xiao-Han Guo, Ray Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.